BAY 41-8543

BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research^[1]. In Vivo: BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output^[1].
BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3?mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30?min. BAY 41-8543 (0.1, 0.3 and 1.0?mg?kg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120?min^[2].
BAY 41-8543 (3?mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival^[2].